Research Article
Formulation and In Vitro Evaluation of Bilayer Tablets of Nebivolol Hydrochloride and Nateglinide for the Treatment of Diabetes and Hypertension
Table 14
Evaluation parameters of Nateglinide sustained release tablets.
| Batch code | Weight variation (%) | Hardness (kg/cm2) | Thickness (mm) | Friability (%) | Drug content (%) |
| N1 | 0.22 | 7.0 | 3.97 | 0.59 | 96.12 | N2 | 0.89 | 5.8 | 3.95 | 0.62 | 97.45 | N3 | 0.55 | 7.2 | 3.99 | 0.60 | 98.10 | N4 | 1.55 | 6.8 | 3.85 | 0.54 | 95.53 | N5 | 1.20 | 6.2 | 3.57 | 0.70 | 98.63 | N6 | 0.89 | 5.5 | 3.84 | 0.69 | 98.84 | N7 | 0.22 | 6.5 | 3.73 | 0.72 | 97.14 | N8 | 0.22 | 5.5 | 3.69 | 0.54 | 101.15 | N9 | 0.55 | 6.8 | 3.89 | 0.52 | 98.68 | N10 | 1.55 | 5.4 | 3.91 | 0.63 | 102.42 | N11 | 0.89 | 6.5 | 4.11 | 0.71 | 97.85 | N12 | 1.88 | 7.0 | 3.90 | 0.51 | 96.81 | N13 | 1.20 | 6.0 | 3.66 | 0.56 | 100.65 |
|
|